Evidence map›Paper›PMID 33028324›Full record

SynthesisBMC health services research2020

Adherence to breast cancer guidelines is associated with better survival outcomes: a systematic review and meta-analysis of observational studies in EU countries.

Ignacio Ricci-Cabello, Adrián Vásquez-Mejía, Carlos Canelo-Aybar, Ena Niño de Guzman, Javier Pérez-Bracchiglione, Montserrat Rabassa, David Rigau, Ivan Solà, Yang Song, Luciana Neamtiu and 3 more

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in BMC health services research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Factors influencing acupuncture regimen completion by breast cancer patients: real-world data from an NCI-designated comprehensive cancer center.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ignacio Ricci-CabelloBalearic Islands Health Research Institute (IdISBa), Palma, Spain.
Adrián Vásquez-MejíaFacultad de Medicina Humana, Universidad Nacional Mayor de San Marcos, Lima, Peru.
Carlos Canelo-AybarCIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Ena Niño de GuzmanIberoamerican Cochrane Centre - Department of Clinical Epidemiology and Public Health, Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Antonio María Claret 167, 08025, Barcelona, Spain. enino@santpau.cat.
Javier Pérez-BracchiglioneInterdisciplinary Centre for Health Studies (CIESAL), Universidad de Valparaíso, Valparaíso, Chile.
Montserrat RabassaIberoamerican Cochrane Centre - Department of Clinical Epidemiology and Public Health, Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Antonio María Claret 167, 08025, Barcelona, Spain.
David RigauIberoamerican Cochrane Centre - Department of Clinical Epidemiology and Public Health, Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Antonio María Claret 167, 08025, Barcelona, Spain.
Ivan SolàCIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Yang SongIberoamerican Cochrane Centre - Department of Clinical Epidemiology and Public Health, Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Antonio María Claret 167, 08025, Barcelona, Spain.
Luciana NeamtiuEuropean Commission, Joint Research Centre (JRC), Ispra, Italy.
Elena ParmelliEuropean Commission, Joint Research Centre (JRC), Ispra, Italy.
Zuleika Saz-ParkinsonEuropean Commission, Joint Research Centre (JRC), Ispra, Italy. zuleika.saz-parkinson@ec.europa.eu.ORCID http://orcid.org/0000-0002-3518-5899
Pablo Alonso-CoelloCIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Funding

Peru Infectious Diseases Epidemiology Research Training ConsortiumD43TW007393 · FIC · UNIVERSIDAD PERUANA CAYETANO HEREDIA · PI Andres G Lescano · 2005 to 2026
$5.9M
European Commission Framework contract 443094 for procurement of services between European Commission Joint Research Centre and Asociación Colaboración Cochrane IberoamericanaFIC NIH HHS D43 TW007393
6 · The paper itself

Abstract

backgroundBreast cancer (BC) clinical guidelines offer evidence-based recommendations to improve quality of healthcare for patients with or at risk of BC. Suboptimal adherence to recommendations has the potential to negatively affect population health. However, no study has systematically reviewed the impact of BC guideline adherence -as prognosis factor- on BC healthcare processes and health outcomes. The objectives are to analyse the impact of guideline adherence on health outcomes and on healthcare costs.

methodsWe searched systematic reviews and primary studies in MEDLINE and Embase, conducted in European Union (EU) countries (inception to May 2019). Eligibility assessment, data extraction, and risk of bias assessment were conducted by one author and crosschecked by a second. We used random-effects meta-analyses to examine the impact of guideline adherence on overall survival and disease-free survival, and assessed certainty of evidence using GRADE.

resultsWe included 21 primary studies. Most were published during the last decade (90%), followed a retrospective cohort design (86%), focused on treatment guideline adherence (95%), and were at low (80%) or moderate (20%) risk of bias. Nineteen studies (95%) examined the impact of guideline adherence on health outcomes, while two (10%) on healthcare cost. Adherence to guidelines was associated with increased overall survival (HR = 0.67, 95%CI 0.59-0.76) and disease-free survival (HR = 0.35, 95%CI 0.15-0.82), representing 138 more survivors (96 more to 178 more) and 336 patients free of recurrence (73 more to 491 more) for every 1000 women receiving adherent CG treatment compared to those receiving non-adherent treatment at 5 years follow-up (moderate certainty). Adherence to treatment guidelines was associated with higher costs, but adherence to follow-up guidelines was associated with lower costs (low certainty).

conclusionsOur review of EU studies suggests that there is moderate certainty that adherence to BC guidelines is associated with an improved survival. BC guidelines should be rigorously implemented in the clinical setting.

trial registrationPROSPERO ( CRD42018092884 ).

Indexed as

Practice Guidelines as TopicBreast NeoplasmsEuropean UnionFemaleGuideline AdherenceHumansObservational Studies as TopicSurvival AnalysisAdherenceBreast cancerClinical guidelinesSurvivalSystematic review

Identifiers

PMID33028324
PMCPMC7542898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.